Prescription medication · SGLT2 Inhibitor
ertugliflozin
Also sold as Steglatro.
Data updated 2026-05-15
- 1,037
- FDA reportsRarely reported
- 8
- InteractionsFew interactions
- $11.43
- Brand price (NADAC)
What the data shows
ertugliflozin (Steglatro) is a prescription SGLT2 Inhibitor, among the least-reported drugs the FDA tracks (1,037 FDA reports), with 8 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$11.43/unit
Generic Available
No
MSD SUB MERCK
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Information not available.
Common side effects
Diarrhea, Nausea, Vomiting
Key warnings
No specific warnings noted. Always follow your prescriber's instructions.
Side Effects (from patient reports)
Based on 1,037 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for ertugliflozin, by number of reports
- Nausea
Nausea
86 reports
- Urinary Tract Infection
Urinary Tract Infection
62 reports
- Vomiting
Vomiting
59 reports
- Fungal Infection
Fungal Infection
58 reports
- Diabetic Ketoacidosis
Diabetic Ketoacidosis
51 reports
- Blood Glucose Increased
Blood Glucose Increased
46 reports
- Dizziness
Dizziness
46 reports
- Diarrhoea
Diarrhoea
43 reports
- Product Dose Omission 29
Product Dose Omission
29 reports
- Decreased Appetite 25
Decreased Appetite
25 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for ertugliflozin each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where ertugliflozin sits
ertugliflozin has more FDA adverse-event reports than 7% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is ertugliflozin; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 1,037 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2013–2025.
Total Reports
1,037
Reports Mentioning Death
12
1.2% of reports — not proof of cause
Hospitalization Reports
290
Top Indication
Type 2 Diabetes Mellitus
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | NAUSEA | 86 |
| 3 | URINARY TRACT INFECTION | 62 |
| 4 | VOMITING | 59 |
| 5 | FUNGAL INFECTION | 58 |
| 7 | DIABETIC KETOACIDOSIS | 51 |
| 8 | BLOOD GLUCOSE INCREASED | 46 |
| 9 | DIZZINESS | 46 |
| 10 | DIARRHOEA | 43 |
| 12 | PRODUCT DOSE OMISSION | 29 |
| 13 | DECREASED APPETITE | 25 |
| 14 | DIABETES MELLITUS INADEQUATE CONTROL | 25 |
| 15 | RASH | 25 |
| 16 | FATIGUE | 23 |
| 18 | ASTHENIA | 21 |
| 19 | INABILITY TO AFFORD MEDICATION | 21 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Known Drug Interactions
7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin. Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2...
Mechanism: Taking these drugs together can increase the risk of a dangerous buildup of lactic acid in the blood, especially if the kidneys are not clearing the medicine properly.
7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions with SEGLUROMET Carbonic Anhydrase Inhibitors Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) with metformin.
Mechanism: Topiramate affects how the body handles acid, which can increase the risk of a serious condition called lactic acidosis when combined with metformin.
Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risks of concomitant use.
Mechanism: Dolutegravir blocks the kidneys from removing metformin from the body, which causes metformin levels to rise and increases the risk of side effects.
Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risks of concomitant use.
Mechanism: Ranolazine prevents the kidneys from properly filtering metformin out of the blood, which can lead to a higher amount of metformin in your system.
Drugs that Reduce Metformin Clearance Clinical Impact: The risk of lactic acidosis may increase due to concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) which increase systemic exposure to metformin Intervention Consider the benefits and risks of concomitant use.
Mechanism: Cimetidine interferes with the body's ability to get rid of metformin through the kidneys, which can cause the drug to build up to unsafe levels.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What are the common side effects of ertugliflozin?
Does ertugliflozin interact with other medications?
What drug class is ertugliflozin?
Related Medications in SGLT2 Inhibitor
Other drugs grouped near ertugliflozin - same-class peers and common alternatives.
acarbose
Precose
Acarbose is a medicine that helps lower blood sugar levels in people with type 2 diabetes.
Compare with ertugliflozin →
alogliptin
Nesina
Compare with ertugliflozin →
bromocriptine
Cycloset
Bromocriptine (Cycloset) is a medicine that acts like dopamine in your body.
Compare with ertugliflozin →
canagliflozin
Invokana
Invokana is a medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Compare with ertugliflozin →
colesevelam
Welchol
Colesevelam is a medicine that helps lower bad cholesterol (LDL-C) and control blood sugar in adults.
Compare with ertugliflozin →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for ertugliflozin: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 1,037.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 1.16%.
- varenicline Δ 0.03 pts · 5,766 reports · Nicotinic Receptor Partial Agonist 1.13%death share
- evolocumab Δ 0.04 pts · 155,068 reports · PCSK9 Inhibitor 1.19%death share
- abaloparatide Δ 0.08 pts · 24,667 reports · PTHrP Analog 1.08%death share
- guselkumab Δ 0.14 pts · 31,164 reports · Anti-IL-23 Monoclonal Antibody 1.30%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on ertugliflozin
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for ertugliflozin
The FDA label for ertugliflozin (sold under brand names such as Steglatro) classifies it as a prescription-only medication in the SGLT2 Inhibitor class. Regulatory labeling describes its approved uses and the patient populations studied in pre-market trials. Official labeling lists 9 commonly reported side effects, including Diarrhea, Nausea, Vomiting.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,037 voluntary reports. The database also lists 8 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: December 20, 2024
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages